Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822890 | 1.00 | KMT2A (0.44) | KMT2AMEN1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL822823 | 0.91 | KMT2A (0.47) | KMT2AMEN1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL9477455 | 0.86 | CA1 (0.52) | KMT2AMEN1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL9477461 | 0.86 | CA1 (0.52) | KMT2AMEN1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL7008412 | 0.83 | KMT2A (0.52) | KMT2AMEN1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL7008421 | 0.83 | KMT2A (0.52) | KMT2AMEN1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4539662 | 0.83 | MAPT (0.46) | KMT2AMEN1SMN1; SMN2CA1CA2 | |
| SCHEMBL10387257 | 0.83 | MAPT (0.46) | KMT2AMEN1SMN1; SMN2CA1CA2 | |
| SCHEMBL4539659 | 0.83 | MAPT (0.46) | KMT2AMEN1SMN1; SMN2CA1CA2 | |
| SCHEMBL8015200 | 0.80 | KDM4E (0.38) | KMT2AMEN1KDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0311053-A2 | Ameliorant of cerebral circulation and optical isomer of nb-818, processes for its production and its use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-12 | — | — | EP | claimed |
| EP-3020704-A2 | CRYSTALLINE POLYMORPHS OF CLEVIDIPINE BUTYRATE | Laboratorios Lesvi, S.L. (ES) | 2016-05-18 | — | — | EP | disclosed |
| EP-2386544-B1 | Preparation of dihydropyridines | LESVI LABORATORIOS SL (ES) | 2016-02-10 | — | — | EP | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8455655-B2 | Preparation of dihydropyridines | LABORATORIOS LESVI, S.L. (ES) | 2013-06-04 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| EP-2386544-A1 | Preparation of dihydropyridines | Laboratorios Lesvi, S.L. (ES) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275825-A1 | PREPARATION OF DIHYDROPYRIDINES | LABORATORIOS LESVI, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| EP-0204317-A2 | 2-Thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0202654-A2 | 5-Carboxy-1,4-dihydropyrimidine derivatives | E.R. Squibb & Sons, Inc. (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| US-4579859-A | HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| EP-0127150-A2 | 2,6-Disubstituted-1,4-dihydropyridine derivative, process for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-05 | — | — | EP | disclosed |
| EP-0116769-A1 | Dihydropyridines | Pfizer Limited (GB) | 1984-08-29 | — | — | EP | disclosed |
| EP-0007293-B1 | 2,6-DIMETHYL-4-(2,3-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID-3-METHYL ESTER-5-ETHYL ESTER HAVING HYPOTENSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING IT | Aktiebolaget Hässle (SE) | 1982-06-23 | — | — | EP | disclosed |
| EP-0031801-A2 | 6-Substituted 4-(2',3'-dichlorophenyl)-2-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diesters having hypotensive properties as well as process for their preparation and pharmaceutical preparations containing same | Aktiebolaget Hässle (SE) | 1981-07-08 | — | — | EP | disclosed |
| US-4264611-A | HYPOTENSIVE AGENTS | AKTIEBOLAGET HASSLE (SE) | 1981-04-28 | — | — | US | disclosed |
| EP-0007293-A1 | 2,6-Dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ester-5-ethyl ester having hypotensive properties, process for its preparation and pharmaceutical preparations containing it | Aktiebolaget Hässle (SE) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | KMT2A 3785/4885MEN1 3169/4885KDM4E 1625/4885 |
| US-20110275825-A1 | PREPARATION OF DIHYDROPYRIDINES | CACNA1C, CACNA1D, CACNB4 | KMT2A 2908/4885MEN1 2310/4885KDM4E 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.